Fifty patients undergoing primary coronary artery bypass surgery and 50 patients undergoing valve surgery received either high-dose aprotinin (2 million units loading dose, 2 million units added to the CPB prime, and 500,000 unitslhr maintenance infusion) or placebo. Mean postoperative blood loss in the first six hours was reduced from 321 ml in the placebo group to 172 ml in the aprotinin group (95 % confidence interval (Cl) for difference = 95 to 189 ml). Seven patients in the placebo group and 16 patients in the aprotinin group did not require transfusion with homologous blood. This study adds to the growing body of evidence that the administration of high-dose aprotinin reduces blood loss and blood transfusion requirements associated with primary cardiac surgery.
Blood conservation is becoming increasingly important in cardiac surgery. Homologous transfusion is expensive and carries a risk of transmitting disease'. This fact is appreciated by the public who expect blood conservation measures to be practised. In the United States of America the risk of contracting hepatitis is 1 per 200 donor units and 1 per 150,000 for human immunodeficiency virus (HIV)'.
Many blood conservation techniques are available 2 • One pharmacological method is by means of aprotinin, a protease inhibitor of bovine origin, discovered in the 1930s. Its effect in reducing blood loss was discovered by chance in 1987 by Van Oeveren et al during an investigation into the effect of aprotinin on the generalized inflammatory reaction associated with cardiopulmonary bypass 3 • A follow-up study by Royston et al in a group of patients having repeat openheart surgery demonstrated a significant reduction in blood loss associated with the use of aprotinin4. Several subsequent studies of aprotinin in cardiac surgery have confirmed these findings'. This study was performed as a further test of the efficacy and safety of high-dose aprotinin for routine cardiac surgery. 
MATERIALS AND METHODS

Study Design
This was a randomized, double-blind, single-centre, parallel group comparison of the efficacy and safety of aprotinin versus placebo in preventing blood loss and reducing blood transfusion requirements in adult patients undergoing routine primary cardiac surgery for coronary artery bypass grafting (CABG) or valve replacement or repair.
Study Population
All patients were 18 years or older and gave written informed consent to enter the trial. Fifty patients scheduled for elective aortic and/or mitral valve replacement or repair, and 50 patients for coronary artery bypass operation requiring at least three distal anastomoses were entered into the study. Approval from the University Ethics Committee was obtained.
Exclusion Criteria
Our aim was to investigate the effects of aprotinin in a group of patients undergoing uncomplicated surgery. Patients with the following conditions were excluded: previous cardiac surgery; severe cardiac failure (left ventricular ejection fraction < 25070); preexisting renal or liver function disturbance (serum creatinine > 150 Ilmolll, AST or ALT > 60 Ilmolll); pregnancy; emergency procedure; necessity for addition of homologous blood to the extracorporeal circuit priming fluid; intra-coronary thrombolysis or angioplasty performed less than three weeks before cardiac surgery; known hypersensivity or previous exposure to aprotinin; an allergic diathesis. Patients taking aspirin preoperatively were not excluded from the study.
Drug Administration
Aprotinin (Trasylol) and placebo solutions were supplied by Bayer AG (Germany). Aprotinin was supplied in 50 ml bottles containing 500,000 Kallikrein Inactivation Units (KIU). The placebo consisted of similar volumes of saline. A high-dose regimen similar to that advocated by Royston et al was used 6 • At the start of the operation 2 million KIU of aprotinin was infused over 30 minutes. This loading dose was followed by a continuous infusion of aprotinin at 500,000 KIU per hour for four hours or until the end of the operation. In addition, 2 million KIU of aprotinin were added to the priming solution of the extra-corporeal circuit.
Patients were randomized to one of two treatment groups (aprotinin or placebo). Patients undergoing coronary artery bypass surgery, and patients undergoing valve replacement or repair were randomized separately (stratified randomization).
Cardiopulmonary Bypass
Cardiopulmonary bypass (CPB) was carried out using a bubble oxygenator with a clear priming solution and moderate hypothermia. The heart was arrested with crystalloid cardioplegia. After an initial dose of 300 units/kg, further heparin was administered as required to maintain the activated clotting time (ACT) > 450 seconds. After weaning from bypass, heparin was neutralized with protamine 1.25 mg per 100 units of heparin administered.
Anaesthetic Technique
The anaesthetic technique was standardized. Patients were induced with fentanyl and etomidate, and anaesthesia maintained using fentanyl to a dose of 50 {Lg/kg together with halothane as required. Patients were ventilated to normocarbia with oxygen-enriched air using pancuronium for muscle relaxation. Inotropic and vasodilator drugs were administered at the discretion of the anaesthetist.
Blood Transfusion Criteria
No specific method of conserving blood was used. Residual blood from the CPB circuit was transfused after bypass. Homologous blood transfusion with packed red cells was allowed only if the haematocrit was less than 20070 during bypass, or less than 26% following bypass, or less than 28% postoperativeiy. Other blood products were given when indicated.
Efficacy and Safety Criteria
The efficacy of aprotinin was evaluated objectively by measurement of blood loss from the mediastinal drains and by comparison of transfusion requirements in the aprotinin and placebo groups. A SUbjective assessment of bleeding after bypass on a 1-4 scale was performed by the surgeon. Blood loss measurements were commenced after reversal of heparin with protamine.
The safety of aprotinin was assessed by comparing the mortality as well as the incidence of other adverse effects between the aprotinin and placebo group. Baseline haematological and biochemical investigations were carried out and monitored until the end of the study, seven days postoperatively.
Statistical Analysis
All results of the statistical analysis are reported as point estimates and 95% confidence intervals for mean differences (or ratios of proportions) between the two treatment groups 7.
RESULTS
Patient Groups
The two groups were demographically similar with respect to sex, age, height and weight (Table 1) . Thirteen patients in the placebo group and 14 in the aprotinin group were taking aspirin preoperatively. The numbers of patients undergoing CABG operations and valve replacements was similar in the two groups ( Table 2) . There was no significant difference in the mean duration of bypass between aprotinin and placebo in the CABG group. In the valve group the mean duration of bypass was significantly longer in those receiving aprotinin ( Table 2) . 
Blood Loss
The mean mediastinal drainage in the first six postoperative hours was 321 ml (range 100-1250) in the placebo group and 172 ml (range 50-1000) in the aprotinin group. The difference between the aprotinin and placebo group (P-A) is 149 ml (95070 Cl 189 ml to 95 ml). This represents a reduction of 46%. The total blood loss in the placebo group was a mean of 783 ml (range 220-3160 ml) compared with a mean of 506 ml in the aprotinin group (range 110-2050 ml). The difference (P-A) was 277 ml (95% Cl 380 to 148 ml). The cumulative mean drainage is graphically demonstrated in Figure 1 .
Surgeon's Assessment
The surgeons' assessment of bleeding after the administration of protamine was assessed as "very low" or "light" (1 or 2 on a scale of 1 to 4) in 100% of patients in the aprotinin group, whereas only 78% of patients in the placebo group received the same assessment. The aprotinin:placebo ratio was 1.29 (95% Cl 1.12 to 1.48). Haemotacrit and Donor Blood Transfusion The quantity of homologous blood transfused amounted to a total of 138 units in the placebo group compared with 92 units in the aprotinin group (a reduction of 33%). Thirty-two per cent of patients in the aprotinin group did not receive any homologous blood as opposed to 14% of patients in the placebo group. The efficacy ratio (A:P) of these proportions is 2.29 (95% Cl 1.07-4.89).
There was a small difference of 1.9% in mean postoperative haematocrits between the two groups, for which the 95% confidence interval was 0.1 to 3.8%.
Mortality and Adverse Events
The study ended after seven days and only early mortality was recorded. There were six deaths among the 100 patients. Four of these deaths were in the placebo group; three had undergone coronary artery bypass surgery. Two deaths occurred in the aprotinin group; both had coronary artery bypass surgery.
No adverse effects could be related to the use of aprotinin. Note: Incidence rate = "number of events"/"number at risk". Where: "number of events" is the number of patients reporting the abnormality at endpoint but not at baseline, and "number at risk" is the number of patients (with non-missing values at baseline and at endpoint) which did not report the abnormality at baseline.
Biochemical and Haematology Results
Low and high values were taken as those falling outside our laboratory range for normal values. In Table 3 , the biochemical results obtained at end point (day 7) are compared with the baseline investigations for each treatment group. The two groups differed only with respect to serum creatinine. Fifteen per cent of patients with a previously normal serum creatinine in the placebo group, compared to 36% in the aprotinin group, developed a high value (> 115 /tmol/I) on the seventh postoperative day. Elevated creatinine values which were considered clinically relevant (> 150 {tmol/l) were identified in two patients in the placebo group (one of whom had a value > 150 {tmol/I preoperatively), and four patients in the aprotinin group (one of whom had an elevated value preoperatively).
A similar comparison for haematology investigations is shown in Table 4 . The incidence rate (number of events/numbers at risk) differed in the two groups only for platelets and white blood cells. In the aprotinin group double the number of the placebo group had a higher than normal platelet or white blood cell count, 18% vs 35070 for platelets and 18% vs 40070 for white blood cells. Note: Incidence rate = "number of events"/"number at risk".
Where: "number of events" is the number of patients reporting the abnormality at endpoint but not at baseline, and "number at risk" is the number of patients (with non-missing values at baseline and at endpoint) which did not report the abnormality at baseline.
DISCUSSION
There have been earlier reports on the use of aprotinin to reduce blood loss. Tice 8 and associates used aprotinin in the 1960s to treat patients with hyperfibrinolysis. Aprotinin was also used in cardiac surgery in the 1970s and early 1980s but in lower doses than the present regimen 6 • There are several possible ways by which aprotinin could interfere with the complex haemostatic defect associated with CPB. The precise mechanism of action is still not completely understood. Aprotinin has an inhibitory effect on contact activation via kallikrein inhibition which affects both fibrinolysis and the intrinsic coagulation pathway. Aprotinin may also protect platelet function. Edmunds et al demonstrated that aprotinin has no direct effect on platelets and have suggested that the platelet-sparing effect of aprotinin may occur by inhibition of plasmin, which is thought to cause platelet aggregation during CPB 9 • Other putative mechanisms of action on the platelet-sparing effect of aprotinin are via stabilization of the platelet adhesive GPlb receptor lO or by modulating prostanoid metabolism in endothelial cells ... 12. The 46% reduction in mean blood loss over the first six hours and the 35070 reduction in mean total blood loss is comparable to that found in other studies 5 where the 24 hour reduction varied between 26070 and 53070. The effect of aprotinin was greater in the first six hours probably on account of the fact that the fluid loss from the mediastinal drains becomes progressively more serous with the passage of time 4
• The 33070 reduction in donor blood usage in the aprotinin group was less than that achieved in other studies which have reported reductions of between 40070 and 8807013. Although the number of patients who did not receive any donor blood doubled (14070 to 32070) with the use of aprotinin, the transfusion requirements were still higher than that reported in other studies. In our study, intra-and postoperative blood transfusions are included.
Both the overall mortality rate of 6070 and the mortality rate of 10070 for the coronary artery bypass surgery group are high. In the aprotinin group, one CABG patient died on the first postoperative day as the result of an arrhythmia. A second patient in this group, who required an intra-aortic balloon pump intraoperatively, died three days later in respiratory failure. In the placebo group three deaths were caused by cardiac failure, bleeding with ventricular fibrillation and perioperative myocardial infarction. A fourth patient died after an unexplained cardiac arrest. No graft occlusion was found at autopsy. No deaths could be attributed to the use of aprotinin.
Concern has been expressed about the possibility of aprotinin causing an increased incidence of graft occlusion in coronary artery bypass surgery and suggestions have been made that it may have a procoagulant action 5 • '4 • In a review of the literature, Royston could find no evidence of an increased risk of vascular occlusion with aprotinin therapy5. Fraedrich et ailS followed up aprotinin and placebotreated patients and found no difference in the incidence of late mortality, angina, nitrate use and patency of internal mammary artery grafts, as measured by subtraction arteriography. Bidstrup et al '6 assessed graft patency by magnetic resonance imaging in 90 patients seven to twelve days postoperatively and found no increased incidence of graft occlusion. This issue still needs to be resolved. Aprotinin, presumably because of its effect on the intrinsic clotting cascade, independently increases the activated clotting time and it has been suggested that ACT values higher than the conventional 450 seconds should be maintained 16. There was a statistically significant difference in the number of patients developing an elevated serum creatinine (> 115 {tmol/I) seven days postoperatively in the aprotinin group compared with the placebo group.
Examination of corresponding clinically important creatinine elevations (> 150 jLmolll) revealed no statistically significant difference between the two groups. In their study Fraedrich et aP' found no difference in serum creatinine and creatinine clearances between the two groups, and concluded that there was little risk of renal impairment if the renal function was normal before the use of aprotinin. Blauhut et al 17 also used aprotinin without adverse effects in patients with normal renal function, but felt that the results of their study could not be extrapolated to patients with preexisting renal dysfunction. Royston', however, used aprotinin with safety in patients with renal failure.
There was a higher incidence of an elevated white blood cell and platelet count in the aprotinin group at the end of the study ( Table 4 ). The significance of this is not known, but was thought to be clinically unimportant.
CONCLUSION
The use of high-dose aprotinin was associated with a significant decrease in blood loss, and a significant increase in the number of patients not requiring homologous blood transfusion. No major complications were associated with the use of high-dose aprotinin. Prophylactic aprotinin therapy could thus become part of an effective blood saving programme.
